Fig. 2From: Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker programProgression free survival analysis in all patients under the combination of BIBW 2992 + gem/cisBack to article page